Participated · Series C · Jul 2026

Ratio Therapeutics is a clinical-stage pharmaceutical company that systematically engineers radiopharmaceuticals using its Trillium pharmacokinetic tuning technology and Macropa chelator platform. Its lead program, [Ac-225]RTX-2358, is in the ATLAS Phase 1/2 trial, and the broader pipeline includes a next-generation GRPR program, additional mono- and bispecific radioligand therapies, and imaging assets. The company has demonstrated external validation through partnered programs, including a collaboration with Novartis on an SSTR2 radioligand therapy. Ratio operates a hybrid manufacturing model with a vertically integrated manufacturing site in Utah, external partners, and diversified isotope supply. Financially, the company recently closed a $70 million Series C that brings total capital raised to over $240 million. Planned near-term activities include advancing the ATLAS trial, filing its fifth IND, moving the next-generation RLT into the clinic, expanding target indications, and scaling manufacturing to support future commercial demand.

Led · Series B · Jul 2026

Claris Biotherapeutics, spun out of the Harvard lab of corneal disease expert Reza Dana, is developing CSB-001 (oremepermin alfa), an eye drop candidate now targeted at limbal stem cell deficiency (LSCD) after an initial neurotrophic keratitis study failed but showed benefit in LSCD patients. The company plans a phase 3 pivotal trial of CSB-001 beginning in the first half of 2027 with a data readout expected within roughly two years. Claris is running a non-interventional natural history study to better understand LSCD and to create a pool of subjects for its phase 3 trial. The biotech has grown from an initial team of five to more than 25 employees and is seeking to establish a physical headquarters. CEO Stephen Brady, who took over June 15, said the company intends to educate providers on diagnosing LSCD and expects to explore additional indications or pipeline expansion if independent and capitalized. Brady also anticipates taking the company public before phase 3 readout, either via IPO or a reverse merger.

Participated · Series D · Jul 2026

AdvanCell develops targeted alpha radiopharmaceutical therapies built around a proprietary Lead-212 platform that combines secure isotope supply, automated manufacturing and scalable production. Its lead program, ADVC001, is a Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer that has shown encouraging Phase 1b anti-tumor activity and favorable tolerability and is currently in Phase 2 clinical development. The company emphasizes vertical integration — spanning isotope supply, advanced manufacturing and clinical development — to address supply and manufacturing constraints for targeted alpha therapies. With integrated operations across North America and Australia, AdvanCell plans to expand U.S. manufacturing infrastructure to support Phase 3 development and future commercial demand. The recent US $315 million Series D financing is intended to advance ADVC001 toward registrational development and accelerate the company’s growing pipeline of targeted alpha therapies.

Participated · Series B · May 2026

Founded in 2021 and headquartered in San Diego, 9amHealth provides AI-enabled virtual specialty care for conditions such as obesity, diabetes, hypertension, and dyslipidemia. The company offers an integrated model combining specialized clinicians (including endocrinologists and obesity medicine specialists), at-home lab testing, medication management, and continuous care. 9amHealth partners with employers, health plans, and pharmacy benefit managers and reports more than $50 million in projected medical and pharmacy savings across two Fortune 100 employers. It has delivered pharmacy cost savings amid rising demand for GLP-1 therapies while improving engagement and clinical outcomes. Backed by investors including Define Ventures, SemperVirens VC, 7Wire Ventures, and The Cigna Group Ventures, the company plans to expand its platform to manage a broader set of high-cost, specialty-level chronic conditions.

Participated · Seed · May 2026

Thea offers a clinically trained AI dermatologist that analyzes users' skin, lifestyle, and existing products to assist in diagnosing issues and recommending treatment protocols. The product experience has driven significant organic traction, generating 200M+ organic views on TikTok and bringing in around 500,000 new users, with hundreds of thousands regularly scanning their faces and receiving personalized recommendations. Users have been able to make in-app purchases of recommended products, and the company tracks product changes and correlated improvements. Over the prior months Thea built a HIPAA-compliant clinical flow supported by board-certified dermatologists to allow AI recommendations to be escalated to human verification, access prescriptions same day, and complete care delivery. Thea plans an initial rollout of that clinical flow in New York and Florida, followed by a fast expansion to all 50 states. The company spent over eight months in market developing and refining the product before announcing the pre-seed round.